Navigation Links
Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
Date:2/14/2008

PITTSBURGH, Feb. 14 /PRNewswire-FirstCall/ -- In response to several inquiries, Mylan Inc. (NYSE: MYL) confirmed today that its matrix design Fentanyl Transdermal System (FTS) is not part of the widespread recall being conducted by Ortho-McNeil-Janssen Pharmaceuticals, Inc. Ortho-McNeil reported that all lots of 25 mcg/hr Duragesic(R) CII patches sold by PriCara in the United States and all 25 mcg/hr Fentanyl patches sold by Sandoz Inc. in the United States are being voluntarily recalled as a precaution from wholesalers and pharmacies because they may have a cut along one side of the drug reservoir within the patch. The result is possible release of Fentanyl gel from the gel reservoir into the pouch in which the patch is packaged, exposing patients or caregivers directly to Fentanyl gel.

Unlike all other U.S. marketed Fentanyl patches, Mylan's FTS is a matrix patch, not a reservoir patch, and therefore does not leak.

Mylan Vice Chairman and CEO Robert J. Coury commented: "We have always believed that our Fentanyl Transdermal System is differentiated from all other Fentanyl patches in the U.S. market because of its unique matrix design. This is an important product characteristic that should be recognized and understood when choosing a Fentanyl Transdermal System."

Mylan's FTS was the first generic Class II narcotic transdermal product approved by the U.S. Food and Drug Administration.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey, L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas. For more information about Mylan, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Restores Availability of Generic Levothyroxine in Florida
2. Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
3. Mylan Declares Quarterly Preferred Stock Dividend
4. Mylan Provides Update Relating to Ongoing Lorazepam and Clorazepate Litigation
5. Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets
6. Mylan Sets Date of 2008 Annual Meeting
7. Mylan Receives $26.2 Million From Exercise of Overallotment Option of Common Stock
8. Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
9. Mylan Completes $2.89 Billion of Equity Financings, Including Exercise of Overallotment Option of Mandatory Convertible Preferred Stock
10. Mylan Prices Offerings of Common Stock and Mandatory Convertible Preferred Stock
11. Mylan Announces Appointment of Joseph F. Haggerty as Senior Vice President and Global General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology: